Our Services

Clinical trials at Bioclinical Research Alliance evaluate the safety and efficacy of medical interventions in humans. These studies follow a carefully designed protocol and assess various aspects of the intervention. Different organizations sponsor clinical trials, and participation is voluntary. The goal is to generate reliable data to inform medical decisions and benefit patients.

Phase I—The first studies in humans are Phase I trials. They are performed with small numbers of patients or healthy volunteers and are used to answer questions such as what dose of the drug is likely to be effective and what side effects might occur.

Phase II – these trials continue this process with more patients. They focus more on how well the treatment or procedure works, perhaps in particular situations or groups of patients.

Phase III – these trials enrol large numbers of patients and compare the effectiveness and safety of the new treatment with that of the existing standard. Information obtained from significant Phase III trials that demonstrate the benefits of a new drug over the existing treatments is sometimes presented to regulatory authorities to obtain a license to market and sell the drug.

Phase IV: Post-marketing surveillance occurs after regulatory approval and involves continued monitoring of the treatment's safety and effectiveness in real-world settings. Researchers collect long-term data to identify any rare or delayed side effects.

Each phase is meticulously designed to adhere to ethical and scientific principles, ensuring the research process's integrity and participants' safety. These phases represent critical milestones in bringing new medical interventions from the laboratory to clinical practice.